CINECA IRIS Institutional Research Information System

DE FRANCIA, Silvia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.035
EU - Europa 4.678
AS - Asia 1.707
SA - Sud America 109
AF - Africa 67
OC - Oceania 51
Continente sconosciuto - Info sul continente non disponibili 7
Totale 12.654
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.977
IT - Italia 1.479
CN - Cina 645
SE - Svezia 496
IE - Irlanda 441
DE - Germania 390
FR - Francia 341
DK - Danimarca 320
SG - Singapore 274
KR - Corea 231
UA - Ucraina 226
FI - Finlandia 178
AT - Austria 139
JP - Giappone 138
GB - Regno Unito 131
IN - India 122
PL - Polonia 114
VN - Vietnam 101
ES - Italia 82
BR - Brasile 59
NL - Olanda 57
RU - Federazione Russa 50
AU - Australia 45
CA - Canada 45
BE - Belgio 44
GR - Grecia 36
TR - Turchia 35
HK - Hong Kong 34
CZ - Repubblica Ceca 32
SN - Senegal 26
CH - Svizzera 22
AR - Argentina 20
TW - Taiwan 17
TH - Thailandia 16
IR - Iran 15
PT - Portogallo 15
CO - Colombia 13
HU - Ungheria 12
MX - Messico 12
SI - Slovenia 12
HR - Croazia 11
IL - Israele 11
LU - Lussemburgo 11
DZ - Algeria 10
EG - Egitto 9
PK - Pakistan 9
RO - Romania 9
RS - Serbia 9
CL - Cile 8
ID - Indonesia 8
UZ - Uzbekistan 8
SY - Repubblica araba siriana 7
ZA - Sudafrica 7
JO - Giordania 6
NZ - Nuova Zelanda 6
SA - Arabia Saudita 6
IQ - Iraq 5
MU - Mauritius 5
MY - Malesia 5
NO - Norvegia 5
BG - Bulgaria 4
EU - Europa 4
NG - Nigeria 4
PE - Perù 4
A1 - Anonimo 3
EC - Ecuador 3
MK - Macedonia 3
BA - Bosnia-Erzegovina 2
BY - Bielorussia 2
KW - Kuwait 2
LV - Lettonia 2
MA - Marocco 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
BD - Bangladesh 1
BT - Bhutan 1
CI - Costa d'Avorio 1
CY - Cipro 1
GE - Georgia 1
GH - Ghana 1
IM - Isola di Man 1
KH - Cambogia 1
LB - Libano 1
MC - Monaco 1
ME - Montenegro 1
MN - Mongolia 1
NP - Nepal 1
PH - Filippine 1
PR - Porto Rico 1
PS - Palestinian Territory 1
UY - Uruguay 1
VE - Venezuela 1
Totale 12.654
Salva come PNG Salva come JPEG
Città #
Chandler 897
Ann Arbor 768
Dublin 427
Beijing 368
Fairfield 299
Torino 284
Houston 264
Ashburn 252
Nyköping 203
Singapore 200
Turin 189
Wilmington 168
Woodbridge 147
Villeurbanne 144
Redwood City 139
Jacksonville 135
Vienna 133
Dearborn 125
Seattle 125
Princeton 123
Medford 122
Cambridge 114
Milan 94
Warsaw 85
Pisa 72
Dong Ket 64
Fremont 57
New York 55
Boston 44
Munich 40
Guangzhou 38
Boardman 31
Brussels 31
Los Angeles 31
Rome 30
Shanghai 30
West Jordan 30
Brno 28
Tokyo 27
Florence 26
Padova 26
Paris 25
Düsseldorf 23
Hefei 23
London 22
Santa Clara 22
Würzburg 22
San Diego 21
Nanjing 17
Bethesda 15
Catania 14
Chengdu 14
Hangzhou 14
Verona 14
Falls Church 13
Hong Kong 13
Madrid 13
Phoenix 13
Seoul 13
Taipei 13
Toronto 13
Washington 13
Bologna 12
Mont-saint-aignan 12
Pune 12
São Paulo 12
Amsterdam 11
Buenos Aires 11
Mumbai 11
Norwalk 11
Siena 11
Valencia 11
Dudelange 10
Hebei 10
Helsinki 10
Jinan 10
Mountain View 10
Bari 9
Bogotá 9
Budapest 9
Hyderabad 9
Nürnberg 9
Canberra 8
Cork 8
Istanbul 8
Polska 8
Rotterdam 8
San Mateo 8
Zurich 8
Columbus 7
Fontenay-sous-bois 7
Kharkiv 7
Maastricht 7
Osaka 7
Palermo 7
Shenyang 7
Shenzhen 7
Bangalore 6
Bangkok 6
Barcelona 6
Totale 7.154
Salva come PNG Salva come JPEG
Nome #
Practical treatment using mitotane for adrenocortical carcinoma. 742
Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. 409
A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. 408
Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children 387
Management of adjuvant mitotane therapy following resection of adrenal cancer. 322
MITOTANE LEVELS PREDICT THE OUTCOME OF PATIENTS WITH ADRENOCORTICAL CARCINOMA TREATED ADJUVANTLY FOLLOWING RADICAL RESECTION. 309
La Medicina delle differenze. Storie di donne, uomini e discriminazioni. 274
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). 269
Subchronic nandrolone administration reduces cardiac oxidative markers during restraint stress by modulating protein expression patterns. 247
RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization 244
Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma 238
Effects of sub-chronic nandrolone administration on hormonal adaptive response to acute stress in rats. 214
A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients. 194
Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment 184
Intense physical exercise increases systemic 11b-hydroxysteroid dehydrogenase type 1 activity in healty adult subjects 181
Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib. 166
PHARMACOGENETIC DETERMINANTS OF PLASMATIC AND INTRACELLULAR TYROSINE KINASE INHIBITORS 166
Role of pharmacogenetics on deferasirox AUC and efficacy 163
Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia 161
Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia 160
Genetic determinants of mitotane pharmacokinetics in adrenocortical cancer patients 153
Differential expression of determinants of glucocorticoid sensitivity in androgen-dependent and androgen-independent human prostate cancer cell lines 152
Procedimento cromatografico di dosaggio di DDT, DDD, DDA, e DDE 151
New hplc-mass spectrometry method for the simultaneous quantification in human plasma of the antileukemia drugs imatinib, dasatinib, and nilotinib 151
Role of Cytochrome P450 in imatinib pharmacokinetics: clinical relevance of inhibitors/inducers concomitant use 148
Il diritto alla scienza medica e le questioni di genere in Così San Tuttə. Diritto alla scienza: istruzioni per l’uso. 141
11betahydroxysteroid dehydrogenase type 1 and 2 activities in bone fragments of patients with rheumatoid arthritis 137
Pharmacogenetic determinants of mitotane pharmacokinetics in adrenocortical cancer patients 135
Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection 133
A new simple HPLC method for measuring mitotane and its two principal metabolites Tests in animals and mitotane-treated patients 132
Steroid resistance in nasal polyposis: role of glucocorticoid receptor and TGF-beta1. 131
Role of cytochrome P450 in imatinib pharmacokinetics: clinical relevance of inhibitors/inducers concomitant use 129
"Procedimento per determinare glifosato e acido aminometilfosfonico in un campione" 129
Differential patterns of glucocorticoid receptors and 11beta hydroxysteroid dehydrogenase activity in androgen-dependent and androgen-independent prostate cancer cell lines. Relevance to glucocorticoid sensitivity. 122
Short QT syndrome in infancy. Therapeutic drug monitoring of hydroquinidine in a newborn infant. 122
In vitro enhancement of anticancer activity of paclitaxel by a Cremophor free cyclodextrin-based nanosponge formulation 121
Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children 117
CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells 112
Efficacia del reintervento chirurgico in pazienti con carcinoma del cortico-surrene recidivo 104
Biological and molecular effects of high doses of anabolic steroids 104
Adjuvant mitotane treatment: a prospective experience at the San luigi Hospital, University of Turin, Italy, USA, 2008 103
La recidiva di carcinoma del cortico-surrene:trattamento chirurgico o chemioterapico? 103
Efficacy of repeat surgery in patients with recurrent adrenocortical cancer (ACC) 100
Valutazione prospettica di pazienti operati radicalmente per carcinoma corticosurrenalico in trattamento con mitotane adiuvante: correlazioni tra indici di massa corporea, livelli di mitotanemia ed efficacia. 99
Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma 98
Clinical relevance of the assessment of deferasirox trough levels in thalassemia patients 97
A prospective study on adjuvant mitotane 96
Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children 96
Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes 93
Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients 90
Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients 88
The San Luigi hospital experience with adjuvant mitotane treatment in patients with adrenocortical cancer following radical resection 87
Influence of single-nucleotide polymorphisms on deferasirox C-trough levels and effectiveness. 85
Deferasirox AUC efficacy cutoff and role of pharmacogenetics 85
Does nephrectomy during adrenalectomy for adrenal cancer improve oncological results? 81
Cremophor free cyclodextrin-based nanosponge formulation for the delivery of paclitaxel 79
New hplc–uv validated method for therapeutic drug monitoring of antifungal agents in acute myeloid leukemia 77
Genetic determinants of mitotane pharmacokinetics in adrenocortical cancer patients 76
Influence of single-nucleotide polymorphisms on deferasirox C-trough levels and effectiveness 76
NURR1 deficiency is associated to ADHD-like phenotypes in mice 75
COVID-19 infection: ACE2, pregnancy and preeclampsia 75
Clinical relevance of deferasirox trough levels in β-thalassemia patients 74
Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. 73
L'esperienza dell'ospedale san Luigi nel trattamento con mitotane adiuvante in pazienti operati radicalmente per carcinoma corticosurrenalico. 72
Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients 72
The combined low-dose dexamethasone suppression corticotropin-releasing hormone test as a tool to rule out Cushing's syndrome 71
Quantification of imatinib plasma levels in patients with chronic myeloid leukemia: Comparison between HPLC-UV and LC-MS/MS 68
New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma 67
Efficacia del reintervento chirurgico in pazienti con carcinoma del cortico-surrene recidivo 67
Influence of single nucleotide polymorphisms on deferasirox Ctrough levels and effectiveness: study on beta-talassemia major affected patients 67
The influence of sex, gender and age on COVID-19 data in the Piedmont region: the virus prefers men 67
Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly 64
EVALUTATION OF THE CONTROL OF PAIN IN PATIENTS WITH BONE METASTASIS UNDERGOING MEDICAL TREATMENT WITH BISPHOSPHONATES 64
Genetic determinants of mitotane pharmacokinetics in adrenocortical cancer patients 64
Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring 63
Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants 63
Determinanti farmacogenetici della farmacocinetica del mitotane: studio condotto su pazienti affetti da carcinoma corticosurrenalico 62
Mitotane 62
The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients 62
Pharmacogenetic of voriconazole antifungal agent in pediatric patients 61
Sex-tailored pharmacology and COVID-19: next steps towards appropriateness and health equity 60
DEVELOPMENT AND VALIDATION OF A HPLC METHOD FOR OROTIC ACID AND OROTIDINE 5’-MONOPHOSPHATE DETECTION IN HUMAN PLASMA AND URINE 59
EFFECT OF SEASONS ON FOUR ANTI-EPILEPTIC DRUGS PLASMA LEVELS 58
GENDER ANALYSIS ON COVID-19 DATA IN PIEMONTE: THE VIRUS PREFERS MEN 57
Single nucleotide polymorphisms of ABCB1 gene influence on intracellular concentrations of dasatinib. 56
Tyrosine kinase inhibitors: the role of pharmacokinetics and pharmacogenetics 56
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. 55
Mineralcorticoidi 54
Effects of germline CYP2W1*6 and CYP2B6*6 single nucleotide polymorphisms on mitotane treatment in adrenocortical carcinoma: A multicenter ENSAT study 54
Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma 53
SEX DIFFERENCES ON MITOTANE CONCENTRATION AND TREATMENT OUTCOME IN PATIENTS WITH ADRENOCORTICAL CARCINOMA 53
THE ROLE OF SURGERY IN THE MANAGEMENT OF RECURRENT ADRENOCORTICAL CARCINOMA: RESULTS OF A RETROSPECTIVE STUDY 52
A current perspective on treatment of adrenocortical carcinoma 52
Mitotane treatment for adrenocortical carcinoma: an overview. 51
Salicylate counteracts streptozotocin induced diabetes mellitus in rat 50
Malattia di Alzheimer: prototipo di malattia di genere? 48
Pharmacogenetic determinants of mitotane pharmacokinetics in adrenocortical cancer patients 48
Phase II study of weekly paclitaxel and sorafenib as second/third line therapy in patients with adrenocortical carcinoma. 47
Effect of Gender and Age on Voriconazole Trough Concentrations in Italian Adult Patients 47
Pharmacogenetic determinants of mitotane pharmacokinetics in adrenocortical cancer patients 46
Totale 12.240
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.750
article - articoli 0
book - libri 0
conference - conferenze 12.404
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.154
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.599 0 0 84 152 137 307 174 122 140 189 134 160
2020/20211.436 167 109 69 72 118 113 98 61 141 106 152 230
2021/20222.256 113 129 134 192 143 166 180 170 105 187 417 320
2022/20232.750 249 269 122 269 237 655 159 176 284 73 179 78
2023/20241.446 163 200 123 77 108 133 55 64 40 134 141 208
2024/2025375 112 207 56 0 0 0 0 0 0 0 0 0
Totale 13.206